




#### **MYELOPROLIFERATIVE NEOPLASM: FRONT LINE**

## **ETCTN 10538**

Venetoclax+ASTX727 (All oral therapy) for CMML, PDS/MPN with excess blasts

Mechanism: BCL-2 selective inhibitor

PI: Jeyakumar Coord: K. McAbee Accrual: 0/5





Open to Accrual Low Accruing Pending Activation/Suspended

### CLL RELAPSED/REFRACTORY: 2L+

## UCI 21-209

LOXO-305 + Venetoclax and Rituximab vs. Venetoclax and Rituximab in previously treated CLL/SLL

Mechanism: BTK inhibitor + BCL2 inhibitor + CD20 marker

PI: Coombs Coord: S. Osorio Accrual: 1/3

#### **CLL NEWLY DIAGNOSED: HIGH RISK**

## S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs Coord: S. Osorio Accrual: 1/10



# NRG-GI008/CIRCULATE

(ctDNA guided tx)

PI: Zell Coord: A. Luna Accrual: 1/5

### **MELANOMA: NON-TREATMENT**

## UCI 19-135

<u>DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and</u> Clinical Outcomes (DECIDE)

> PI: Yamamoto Coord: A. Reipolska Accrual: 64/70

